AXIM BIOTECHNOLOGIES, INC.
AXIM · OTCMCIK 1514946fmd_0FBEJCQRRBM3K4VWEZEZJ4TCCKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Jun 30, 2024, 54 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Operations and maintenance | – | – | – | – | – | – | – | – | – | – |
| Gross profit | 0 | (0) | (0) | 0 | 0 | 0 | 0 | – | – | – |
| Research and development | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 1 | 9 | 3 | – | – | – | – | 6 | 4 | 2 |
| Total operating expenses | 1 | 10 | 4 | 3 | 5 | 3 | 5 | 14 | 5 | 3 |
| Operating income | (1) | (10) | (4) | (3) | (5) | (3) | (5) | (14) | (5) | (3) |
| Non-interest expense | – | 0 | 0 | – | – | – | – | – | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Interest and investment income | – | – | 0 | 0 | 0 | – | 0 | 0 | – | – |
| Other non-operating income (expense) | 0 | 0 | (2) | (1) | (2) | 0 | 1 | 2 | 2 | 5 |
| Income before taxes | (1) | (10) | (6) | (4) | (7) | (3) | (6) | (16) | (6) | (8) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (1) | (10) | (6) | (4) | (7) | (3) | (6) | (16) | 0 | 0 |
| Net income | (1) | (10) | (6) | (4) | (7) | (6) | (6) | (16) | (6) | (8) |
| Net income to common shareholders | – | – | (7) | (4) | (7) | (6) | (6) | (16) | (6) | – |